Quantum BioPharma

QNTM

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$3.24

-0.13 (-3.86%)

Market Cap

$14.5M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+511.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 538K (2021) → 3.3M (2025)

Quantum BioPharma Ltd. is a small Canadian pharmaceutical company focused on developing drugs for addiction and mental health conditions. Its main programs include treatments targeting alcohol use disorder and other substance dependencies, with patients and healthcare providers as the end customers. The company is in the clinical-stage, meaning it is still testing its drugs and has not yet brought a product to market.

Quantum BioPharma does not currently generate meaningful revenue, which explains the zero gross margin figures. It funds its operations primarily through equity financing, which is common for early-stage drug developers. The company operates mainly in Canada and the United States, but it is very small with a market cap near zero. The key risk here is straightforward: clinical-stage companies frequently fail to get drugs approved, and without a successful trial result or partnership with a larger pharmaceutical company, the business could run out of funding before reaching commercialization.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+60.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$3M/ year

↓ Declining (-55% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

8.0%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~8 months

$4M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Quantum BioPharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-195.2%

Weak — -195.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

1.46

Elevated debt (1.46)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial